DB05328ExperimentalSmall molecule
VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
- Mechanism
- Curator reviewed
VGV-1 is appears to work through a mechanism that involves the use of the immune system, rather than attacking the virus itself. VGV-1 also has minimal side effects and is projected to be cost-effective. Because a treatment cycle with VGV-1 consists of just 16 injections, it is substantially less expensive than ART or HAART which require that drugs be taken once a day, or even more frequently.
- Primary indication
- Investigated for use/treatment in HIV infection.Curator reviewed
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with VGV-1, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account